Cláudia Bitti Barroso

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
We report our experience in 4 patients with chronic myeloid leukemia (CML) who had discontinued imatinib as a result of adverse events and had switched to dasatinib. The chronic phase (n 2) and accelerated phase (n 2) CML patients received dasatinib at starting dose of 100 and 140 mg once daily, respectively. Reappearance of hematological toxicity was(More)
  • 1